IMUX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 20.43%, SMA50 38.27%, SMA200 19.33%). The stock’s 14-day RSI is 64.8 (firm momentum), while the ATR of 0.09 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -29.8% below its high and over 87.22% above its low. Average 10-day trading volume of 165.00 thousand shares is below the 3-month average of 264.35 thousand, indicating normal recent market interest.

Immunic, Inc. has 98.65 million shares outstanding. The public float is 65.25 million shares, elevated short interest at 10.10% of float. This equals 9.78 million shares. The short ratio is 8.91 days. Institutional investors hold 56.21% of the float. Insiders own 1.02%. Muehler Andreas holds 297.99 thousand shares, Groeppel Manfred has 278.83 thousand shares and Rudick Richard Alan has 230.38 thousand shares.

Immunic, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.95. This means the shares are trading above this model’s fair value.

Immunic, Inc. (NASDAQ:IMUX) closed at $14.64 USD, losing -$0.13 (-0.88%) from the previous close of $14.77. The stock is currently mid-range between its 52-week high and low $5.06 and $15.84. With a market capitalization of about $144.48 million, Immunic, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.38). Key stats such as the average daily volume over the past year has been around 269.12 thousand shares, in line with its 52-week average. Headquartered in New York City, NY, Immunic, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel Vitt, the company employs approximately 92 people and listed since April 17, 2014. Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions.

Immunic, Inc. generated EPS of -$0.87 over the past year. Five-year average earnings growth is 26.01%. Wall Street analysts project EPS growth of 29.25% annually over the next five years. The latest quarter delivered EPS of -$1.08. The next quarter is forecast at -$0.09. Next year's EPS is expected at $14.90. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $2.50. The high target offers 84.43% upside. The low target suggests -82.92% downside. The mean target is $9.96. This offers -31.97% upside. Immunic, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 13, 2026, missed forecasts by 52.11%. The prior quarter beat by 1050.64%. Over the last six quarters, Apple has recorded several small beats. These include 13.64% in March 31, 2025.

Immunic, Inc. trades at a P/E ratio of -2.46, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.94 suggesting the stock is closer to book value. The P/FCF stands at -1.79, also above market averages.

Immunic, Inc. (NASDAQ:IMUX) shares are up 20.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Immunic, Inc. trading at a premium to the broader market with a P/E of -2.46. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.03, suggesting 43.65% upside. Our AI forecast model points to short-term strength (4.78% over two weeks), a medium-term rise (95.08% over three months), and a longer-term gain (172.06% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Immunic, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.78%, with price expected at $15.34 by July 27, 2026, within a range of $14.22 to $16.41 3-Month Outlook: Projected rise of 95.08%, reaching $28.56 by October 08, 2026, with a range of $28.17 to $29.03. 1-Year Outlook: Projected gain of 172.06%, with price at $39.83 by July 13, 2027, within a range of $30.00 to $53.49.